These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35952367)

  • 1. Discovery of the First Selective IDO2 Inhibitor As Novel Immunotherapeutic Avenues for Rheumatoid Arthritis.
    He G; Wan S; Wu Y; Chu Z; Shen H; Zhang S; Chen L; Bao Z; Gu S; Huang J; Huang L; Gong G; Zou Y; Zhu Q; Xu Y
    J Med Chem; 2022 Nov; 65(21):14348-14365. PubMed ID: 35952367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.
    Merlo LMF; Grabler S; DuHadaway JB; Pigott E; Manley K; Prendergast GC; Laury-Kleintop LD; Mandik-Nayak L
    Clin Immunol; 2017 Jun; 179():8-16. PubMed ID: 28223071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.
    Merlo LMF; Pigott E; DuHadaway JB; Grabler S; Metz R; Prendergast GC; Mandik-Nayak L
    J Immunol; 2014 Mar; 192(5):2082-2090. PubMed ID: 24489090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses.
    Merlo LMF; DuHadaway JB; Montgomery JD; Peng WD; Murray PJ; Prendergast GC; Caton AJ; Muller AJ; Mandik-Nayak L
    Front Immunol; 2020; 11():1861. PubMed ID: 32973768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.
    He X; He G; Chu Z; Wu H; Wang J; Ge Y; Shen H; Zhang S; Shan J; Peng K; Wei Z; Zou Y; Xu Y; Zhu Q
    J Med Chem; 2021 Dec; 64(24):17950-17968. PubMed ID: 34854662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.
    Merlo LM; Mandik-Nayak L
    Clin Med Insights Pathol; 2016; 9(Suppl 1):21-28. PubMed ID: 27891058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism.
    Merlo LMF; Peng W; DuHadaway JB; Montgomery JD; Prendergast GC; Muller AJ; Mandik-Nayak L
    J Immunol; 2022 Feb; 208(3):571-581. PubMed ID: 34965962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
    Röhrig UF; Majjigapu SR; Caldelari D; Dilek N; Reichenbach P; Ascencao K; Irving M; Coukos G; Vogel P; Zoete V; Michielin O
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4330-3. PubMed ID: 27469130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors.
    Meininger D; Zalameda L; Liu Y; Stepan LP; Borges L; McCarter JD; Sutherland CL
    Biochim Biophys Acta; 2011 Dec; 1814(12):1947-54. PubMed ID: 21835273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of IDO1 and IDO2 on the B Cell Immune Response.
    Merlo LMF; Peng W; Mandik-Nayak L
    Front Immunol; 2022; 13():886225. PubMed ID: 35493480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the kynurenine pathway in Indoleamine 2, 3 dioxygenase deficient mice with inflammatory arthritis.
    Kolodziej L
    Transgenic Res; 2013 Oct; 22(5):1049-54. PubMed ID: 23417792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model.
    Merlo LM; Bowers J; Stefanoni T; Getts R; Mandik-Nayak L
    Clin Pathol; 2020; 13():2632010X20951812. PubMed ID: 32924009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.
    Trabanelli S; Očadlíková D; Ciciarello M; Salvestrini V; Lecciso M; Jandus C; Metz R; Evangelisti C; Laury-Kleintop L; Romero P; Prendergast GC; Curti A; Lemoli RM
    J Immunol; 2014 Feb; 192(3):1231-40. PubMed ID: 24391212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
    Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Challenges for IDO2 as Target in Cancer Immunotherapy.
    Mondanelli G; Mandarano M; Belladonna ML; Suvieri C; Pelliccia C; Bellezza G; Sidoni A; Carvalho A; Grohmann U; Volpi C
    Front Immunol; 2021; 12():679953. PubMed ID: 33968089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1.
    Pantouris G; Serys M; Yuasa HJ; Ball HJ; Mowat CG
    Amino Acids; 2014 Sep; 46(9):2155-63. PubMed ID: 24875753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors.
    Li J; Li Y; Yang D; Hu N; Guo Z; Kuang C; Yang Q
    Eur J Med Chem; 2016 Nov; 123():171-179. PubMed ID: 27475108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.
    Fatokun AA; Hunt NH; Ball HJ
    Amino Acids; 2013 Dec; 45(6):1319-29. PubMed ID: 24105077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase.
    Gonzalo-Gil E; Pérez-Lorenzo MJ; Galindo M; Díaz de la Guardia R; López-Millán B; Bueno C; Menéndez P; Pablos JL; Criado G
    Arthritis Res Ther; 2016 Apr; 18():77. PubMed ID: 27036118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.
    Merlo LM; DuHadaway JB; Grabler S; Prendergast GC; Muller AJ; Mandik-Nayak L
    J Immunol; 2016 Jun; 196(11):4487-97. PubMed ID: 27183624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.